H
ereditary hemorrhagic telangiectasia (HHT) is an inherited autosomal dominant vascular disorder that affects 1:5000 people worldwide. 1 More than 85% of HHT cases are caused by heterozygous mutations in the endothelial surface receptors endoglin ([ENG] mutated in HHT1) and ACVRL1 (hereafter referred to as ALK1, mutated in HHT2). 2, 3 HHT patients develop arteriovenous malformations (AVMs), which are direct connections between arteries and veins without an intervening capillary bed. Because capillaries normally slow blood flow to allow gas exchange with surrounding tissues, high-flow AVMs can lead to hypoxia as well as hemorrhage due to fragility of the vascular wall. AVMs in HHT patients appear most often in the skin, oral cavity, nasal, and gastrointestinal (GI) tract mucosa, lung, liver, and brain. 1, 4 Small AVMs in the skin and mucus membranes are called telangiectasias; rupture of these lesions leads to frequent epistaxis, GI bleeding, and anemia, all of which are major quality of life issues for HHT patients. Larger AVMs in liver, lung, or brain may additionally cause life-threatening conditions such as high output heart failure and stroke. 4 ENG and ALK1 are receptors for transforming growth factor-β (TGF-β)/bone morphogenetic protein (BMP) family ligands, which include 33 members in humans 5, 6 Among these, BMP9 and 10 bind with picomolar affinity to ALK1 and ENG. BMP9 and 10 are produced in liver and heart, respectively, and circulate through the bloodstream until they bind to ALK1 and type II receptors, 7 with ENG facilitating ligand binding. 8 Activated ALK1 phosphorylates cytoplasmic regulatory SMAD proteins SMAD1, SMAD5, or SMAD8, which bind SMAD4, enter the nucleus, and regulate gene expression. 8 Mutations in SMAD4 cause a combined juvenile polyposis (JP)-HHT syndrome that accounts for <5% of HHT cases. 9 Patients with this disorder have the vascular problems associated with HHT as well as an increased risk of developing intestinal polyps at an early age; these polyps may become cancerous.
9 SMAD4 functions as a common downstream effector of BMP and TGFβ signaling, and its implication in AVM pathogenesis as a downstream effector of ALK1-ENG signaling is unclear. Several studies have examined endothelial SMAD4 function. [10] [11] [12] One study used constitutive Tie2-mediated endothelial specific Smad4 deletion, which led to embryonic lethality due to cardiovascular defects. 10 In the other study, Smad4 was deleted using a constitutive Cre line active in brain endothelial cells (ECs), which led to massive intracranial hemorrhage and postnatal lethality. 11 Tamoxifen inducible RosaCreER-mediated Smad4 deletion at midgestation led to increased coronary artery diameter 48 hours later due to failure of endothelial cell alignment in the direction of blood flow. 12 More recently, while this paper was under review, Crist et al reported that postnatal endothelial-specific Smad4 deletion led to retinal AVMs. 13 In addition to SMAD4, the ALK1 receptor activates various SMAD4-independent pathways including JNK (c-JUN N-terminal kinase) and ERK (extracellular signalregulated kinase), 14 and DROSHA-mediated microRNA maturation. 15 Implications of these pathways in AVM pathogenesis and HHT are largely unknown, but a recent study showed that mice or zebrafish lacking Drosha in ECs developed AVMs and that some HHT patients presented loss of function mutations in the Drosha gene. 16 We, and others, have shown that blocking BMP9/10 signaling using neutralizing antibodies or postnatal endothelial-specific deletion of ALK1 and ENG in mice all lead to HHT-like AVM formation. [17] [18] [19] [20] [21] [22] These in vivo models have revealed that flow-induced shear stress enhances pathway activation, in turn mediating vascular quiescence by inhibiting endothelial cell proliferation and promoting pericyte recruitment. 23 Mechanistically, blocking BMP9-ALK1-ENG signaling promotes endothelial PI3K (phosphatidylinositol 3-kinase)/AKT (protein kinase B) activation. 17, 19 Alk1-deficient endothelial cells showed enhanced phosphorylation of the PI3K target AKT due to decreased PTEN (phosphatase and tensin homolog) signaling, which normally opposes PI3K. Pharmacological PI3K inhibition prevented AVM formation in Alk1-deficient mice 19 and decreased diameter of AVMs in Eng mutants. 17, 19 Moreover, an increase in PI3K Here we addressed whether SMAD4 was required for AVM formation and regulation of PI3K activity. We show that postnatal endothelial Smad4 ablation causes AVM formation in retinas, GI tract, and brain. We further provide evidence that SMAD4 attenuates CK2 expression and counteracts flow-induced PI3K/AKT1 signaling to prevent AVM formation. Collectively, the data show that SMAD4 acts downstream of BMP9/10-ALK1 in AVM pathogenesis in mice and identify new targets with the potential to prevent vascular malformations in HHT patients.
METHODS
All data and the methods supporting this study's findings are available from the corresponding authors on request.
Animal Experiments
Mice were maintained under standard specific pathogenfree conditions, and all animal procedures performed were reviewed and approved by the Institutional Animal Care Use Committee of Yale University. The supplementary material contains a list of all mouse strains and protocols. histone H3] #06570; 1:500; EMD Millipore), anti-Ephrin type B receptor 4 (EPHB4) (#AF446, 1:100; R&D systems), anti-uncoordinated 5b (UNC5B) (#AF1006, 1:100; R&D systems), and anti-Neuropilin-2 (NRP2) (#AF567, 1:100; R&D systems).
Antibodies
For western blotting: anti-ALK1 (7R-49334, 1:1000; Fitzgerald), anti-SMAD4 (#38454, 1:1.000; Cell Signaling), anti-pAKT (#4060, 1:1.000; Cell Signaling), anti-AKT (#9272, 1:1.000; Cell Signaling), anti-phospho-PTEN (pPTEN) (#9549, 1:1.000; Cell Signaling), and anti-PTEN (#9188, 1:1.000; Cell Signaling) and anti-β-actin (#A1978 1:3000; Sigma).
Appropriate secondary antibodies were fluorescently labeled (Alexa Fluor donkey antirabbit, Alexa Fluor donkey antigoat) or conjugated to horseradish peroxidase (antirabbit and antimouse IgG [H+L], 1:8.000; Vector Laboratories).
Mouse Lung Endothelial Cell Isolation
Mouse Lung Endothelial Cells (mLEC) were isolated from collagenase-digested lung tissue using rat antimouse CD31 (cluster of differentiation 31) monoclonal antibody-coated Dynabeads (#11035; Invitrogen) and cultured in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 μg/mL streptomycin, 100 μg/mL endothelial cell mitogen (Biomedical Technologies, Inc.), and 10 U/mL heparin for 10 days before RNA isolation or antibody labeling.
Quantitative Real-Time Polymerase Chain Reaction (PCR)
RNAs from mLECs were purified using RNeasy-kit (Qiagen). RNA was reverse transcribed using SuperScript III (Invitrogen) and quantitative PCR were assayed using the corresponding primers (Qiagen): MmSmad4 (QT00130585), MmId1 (QT0024 0219), MmAcvrl1 (QT00161434), MmEng (QT00148981), MmJag1 (QT00115703), and MmEphB4 (QT00120295), MmUnc5b (QT00167846), MmNrp2 (QT00154427), HsCK2A2 (QT00014385), and HsLKB1 (QT01008980). The expression levels were normalized to MmActb (QT00095242) and HsACTB (QT01680476).
Immunostaining
For angiogenesis studies the eyes of P5/P6 pups were prefixed in 4% PFA for 17 min at room temperature. Retinas were dissected, blocked for 30 min at room temperature in blocking buffer (1% fetal bovine serum, 3% BSA, 0.5% Triton X-100, 0.01% Na deoxycholate, 0.02% Na azide in PBS at pH 7.4) and then incubated with specific antibodies in blocking buffer overnight. The next day, retinas were washed and incubated with IB4 together with the corresponding secondary antibody for 1h at room temperature and mounted in fluorescent mounting medium (DAKO, USA). High-resolution pictures were acquired using a Leica SP5 confocal microscope with a Leica spectral detection system (Leica 15 SP detector), and the Leica application suite advanced fluorescence software. Quantification of retinal vasculature was done using ImageJ and then Prism 7 software for statistical analysis.
Cell Culture and Small Interfering RNA Transfection
Human umbilical vein endothelial cells (HUVECs) were obtained from the Yale University Vascular Biology and Therapeutics Core Facility and cultured in EGM2-Bullet kit medium (CC-3156 & CC-4176, Lonza). Depletion of SMAD4 and ALK1 was achieved by transfecting 25 pmol of small interfering RNA (siRNA) against SMAD4 (Qiagen, mixture of 4 siRNAs: SI03089527, SI03042508, SI00076041, SI00076020) or against ALK1 (Qiagen, mixture of 2 siRNAs: S102659972 and S102758392) using Lipofectamine RNAiMax (Invitrogen). Transfection efficiency was assessed by western blotting and quantitative PCR (qPCR). Experiments were performed 60 hours posttransfection and results were compared with siRNA CTRL (ON-TARGETplus Non-Targeting Pool D-001810-10-05). Cells were starved for 16 hours in serum-free medium and then treated with 10 ng·ml -1 of BMP9 for 2 hours. HUVECs in complete medium were treated for 2 hours with 10 μg/mL TBCA (tetrabromocinnamic acid) or CX-4945 and the effect on PTEN and AKT phosphorylation were detected by Western Blotting.
To determine the half-life of SMAD4 and ALK1, HUVECs were starved in EBM-2 and treated with 100μg/mL of cycloheximide for the timepoints indicated. 
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EXPOSURE OF ENDOTHELIAL CELLS TO SHEAR STRESS
Proliferation Assay
We performed the proliferation analysis using Click-iT EdU Alexa Fluor 488 Imaging kit (Life Technologies). P6 pups were injected with 200 μg of EdU (5 mg/mL) and killed 4 hours later. EdU staining was done according the manufacturer's protocol.
Western Blotting
Cells were lysed with Laemmli buffer including phosphatase and protease inhibitors (Thermo Scientific, 78420, 1862209). 20 μg of proteins were separated on 4% to 15% Criterion precast gels (567-1084, Biorad) and transferred on 0.23 um nitrocellulose membranes (Biorad). Western blots were developed with chemiluminescence horseradish peroxidase substrate (Millipore, WBKLS0500) on a Luminescent image Analyzer, ImageQuant LAS 4000 mini (GE Healthcare). Bands were quantified using ImageJ.
Statistical Analysis
All data are shown as mean±standard error of the mean. Mann-Whitney U was used to compare 2 groups. Oneway ANOVA was used to compare more than 2 groups followed by appropriate post hoc multiple comparison procedure (Tukey multiple comparisons test). Two-way ANOVA was used when testing the effects of 2 different factors, followed by Sidak multiple comparisons test. To construct the survival curves we have used the KaplanMeier method. P value <0.05 was considered to be statistically significant. Statistical analyses were performed for all quantitative data using Prism 6.0 (Graph Pad).
RESULTS
Postnatal Endothelial-Specific Smad4 Deletion Leads to AVM Formation
To test the function of Smad4 during postnatal angiogenesis, we created tamoxifen inducible endothelial specific Smad4 knockout mice (Smad4 iΔEC ) by crossing Smad4 fl/fl mice with a Cdh5-Cre ERT2 driver line. Gene deletion was induced by 3 intragastric injections of 100 μg tamoxifen (Tx) between postnatal day 0 (P0) and P2 and mice were examined at P6 ( Figure 1A ). IB4 labeling of retina vessels showed absence of AVMs in Tx-injected Cre negative control (Ctrl) littermates, while Smad4 Figure 1D , 1E, and 1F). Efficient Smad4 and Alk1 gene deletion was validated by qPCR from P6 mouse lung endothelial cells (mLECs; Figure 1G ). Smad4 iΔEC mice died 6 to 8 days after gene deletion, while Alk1 iΔEC mice died within 48 hours ( Figure 1H ). Autopsy revealed hemorrhage in the lungs of Alk1 iΔEC and Smad4 iΔEC mice, as also observed by others in such mice, hence hemorrhage is a likely cause of death. 13, 21 To identify the presence of AVMs in other vascular beds, latex blue dye was injected into the left ventricle of P6 Ctrl, Smad4 iΔEC , and Alk1 iΔEC mice. The latex dye could not cross the capillary beds and remained confined to arterial branches in the pial vessels of the head ( Figure 1I ) and in the GI tract ( Figure 1M and 1P) of Ctrl mice. In both Smad4 iΔEC and Alk1 iΔEC pups, the latex also perfused veins via AVMs present in the pial vessels (arrows in Figure 1J and 1K) and GI tract (arrows in Figure 1N , 1O, 1Q, and 1R). The frequency of AVMs and latex perfused veins in Smad4 iΔEC mice was higher in the pial vessels and lower in the GI tract when compared to Alk1 iΔEC pups ( Figure 1L and 1S). We next determined kinetics of AVMs formation in Smad4 iΔEC and Alk1 iΔEC mice, by treating with 100μg Tx at postnatal day 2 (P2) and P3 in Cre-negative littermate controls and Smad4 iΔEC pups and comparing the phenotype to Alk1 iΔEC pups injected at P3 (Suppl. Fig.1A-D) . Efficient Smad4 and Alk1 deletion (>65%) was confirmed by qPCR from mLECs at P5 (Suppl. 
Flow-Induced Altered Cell Behavior in Smad4
iΔEC Retinas
Similar to BMP9/10-ALK1 signaling-deficient pups 23 the ORIGINAL RESEARCH ARTICLE vascular plexus close to the optic nerve, mainly at the first arterial branch point, where blood flow is high (Figure 2A) . By contrast, an increase in vessel branching and vascular density was detected only in the sprouting front, where blood flow is low ( Figure 2B and 2C).
To confirm that shear stress contributes to AVM formation, we immunolabeled retinas with antibodies against KLF4, a transcription factor regulated by flowinduced shear stress 24 in combination with ERG1,2,3, a transcription factor that specifically labels EC nuclei. 
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The sprouting front of Ctrl and Smad4 iΔEC retinas contained few ERG123+ KLF4+ double positive ECs (Figure 2D , 2E, and 2H). Most of the ERG123+ KLF4+ double positive ECs were detected in the vascular plexus, where the blood flow is the highest (Figure 2F through  2H) . 26 Quantification of KLF4+ labeling intensity per ERG1,2,3 positive nuclei revealed higher levels in arterial cells when compared to veins or capillaries in Ctrl retinas ( Figure 2F and 2H), confirming that KLF4 staining can be used as a EC flow marker in the retina. The KLF4 staining intensity was higher in Smad4 iΔEC arteries, veins and capillaries involved in AVMs when compared with Ctrl vessels (Figure 2F retinal plexus were strongly KLF4+ ( Figure IIA and IIB in the online-only Data Supplement), suggesting that flow-induced shear stress, but not Smad4 deletion, affected KLF4 expression in the AVMs.
Physiological shear stress maintains endothelial quiescence by inhibiting proliferation and inducing recruitment of pericytes. 27, 28 To (Figure 2I to 2M) . In addition, labeling for NG2-a pericyte marker-showed that pericyte coverage was significantly decreased in the AVMs, whereas it was unaffected in the sprouting front ( Figure 2N to 2R ).
Arterial-Venous Identity Changes on Smad4 Deletion
Because ALK1 signaling blockade affects arterial-venous marker expression, 21 we studied the identity of endothelial cells in Smad4 iΔEC retinas. Staining of Ctrl P6 retinas with an antibody against SMA showed coverage of arteries, but not of capillaries and veins, while Smad4 iΔEC retina vessels exhibited decreased arterial and increased venous SMA coverage ( Figure 3A to 3C ). AVMs were partially covered by SMA ( Figure 3B and 3C), suggesting that loss of identity or increased venous muscularization due to increased blood flow occurred in Smad4 iΔEC AVMs. qPCR analysis on mLECs isolated from Smad4 iΔEC versus Ctrl mice revealed efficient Smad4 deletion and downregulation of Id1, one of the direct target genes regulated by BMP9-ALK1 signaling 29 ( Figure 3D ). Smad4 mutant cells also showed a slight, albeit significant, decrease in the expression levels of Eng and Alk1 ( Figure 3D ). mRNA levels of the arterial genes Jag1 and Unc5b were decreased, whereas expression of the venous markers EphB4 and Nrp2 were increased in Smad4-deficient mLECs ( Figure 3D ). qPCR data were confirmed by immunolabeling. Smad4-depleted arteries lost JAG1 ( Figure 3E and 3F) and UNC5B ( Figure 3G and 3H), and gained EPHB4 ( Figure 3I and 3J) and NRP2 expression ( Figure 3K and 3L) , revealing arterial-venous identity changes associated with AVM formation in these mice.
In addition to BMP9-ALK1 targets, TGFβ regulated genes CDKN1A encoding P21 and Serpine1 encoding PAI1 30 were also downregulated in HUVECs transfected with a siRNA against SMAD4, and in Smad4 mutant mLECs ( Figure IIIA and IIIB in the online-only Data Supplement). Noncanonical TGFβ signaling pathways pP38 and pJNK were not affected by SMAD4 deletion ( Figure IIIC and IIID in the online-only Data Supplement).
Enhanced Flow-Induced AKT Signaling in SMAD4 Mutant AVMS
We next tested effects of SMAD4 deletion on AKT signaling. While SMAD4 siRNA completely abolished SMAD4 protein expression 60 hours posttransfection in HUVECs grown in serum-free medium, SMAD4 deletion significantly increased AKT phosphorylation at serine 473, as also seen with ALK1 knockdown cells ( Figure 4A and 4B) . It is interesting that subjecting HUVECs to flow resulted in a strong enhancement of AKT phosphorylation, which was suppressed by BMP9 treatment in CTRL ( Figure 4C through 4E) but not in ALK1 knockdown cells ( Figure 4D and 4G). SMAD4 knockdown cells treated with BMP9 exhibited attenuated suppression of flow-induced AKT phosphorylation ( Figure 4C and 4F) . These results reveal that BMP9 antagonizes flow-induced AKT activation in an ALK1-and partially SMAD4-dependent manner.
Smad4-depleted mLECs also exhibited increased AKT phosphorylation compared to ECs from Ctrl littermate mice ( Figure 4H and 4I) . Moreover, Smad4-deficient retinas showed an increase in the AKT effector ribosomal pS6 when compared to Ctrl retinas ( Figure 4J , 4K, and 4N). Nuclear FOXO1 localization, which is inhibited by AKT signaling 31 ( Figure 4J ), was strongly decreased in the vascular plexus of Smad4 mutants when compared to Ctrl retinas ( Figure 4L and 4N) . Nuclear localization of the cMYC transcription factor, which is negatively regulated by FOXO1 32 ( Figure 4J ), was strongly increased in the AVMs of Smad4 iΔEC retinas when compared to the vascular plexus of Ctrl retinas ( Figure 4M and 4N ). In addition, isolated Smad4 mLECs showed a decrease in SMAD4 ( Figure IVA 
PI3K/AKT Signaling Inhibition Reduces AVM Formation in Smad4 iΔEC Mice
To test whether PI3K/AKT signaling inhibition could prevent AVM formation in Smad4 iΔEC mice, we induced gene deletion in Smad4 iΔEC pups by injecting Tx at P0 to P2 and further treated the mice with PBS versus Wortmannin (a nonselective PI3K inhibitor, PI3Ki, 33 ) at P3 to P5 (Figure 5A) . Analysis of retinal vasculature at P6 showed that PI3K inhibition prevented AVM formation in Smad4 iΔEC retinas ( Figure 5B through 5D ). PI3K inhibition also normalized expression of ribosomal pS6, nuclear FOXO1, and cMYC ( Figure 5E through 5G Figure 5L ). However, downregulation of AKT1 failed to prolong the survival of Smad4 iΔEC mice ( Figure 5M ).
SMAD4 Controls PTEN and AKT Phosphorylation Via CK2
We previously showed that BMP9-ALK1 signaling represses PI3K/AKT activity by dephosphorylating and 
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stabilizing PTEN at the cell membrane. 19, 22 To investigate if this effect was dependent on SMAD4 signaling, we treated CTRL and SMAD4 siRNA depleted cells with BMP9 ( Figure 6A ). Two hours of BMP9 stimulation decreased phosphorylation of AKT at Ser473 and of PTEN at Ser380/Thr382/383 ( Figure 6A and 6B) . SMAD4 depletion induced an increase of AKT and PTEN phosphorylation, and BMP9 failed to suppress 
this increase ( Figure 6A and 6B), consistent with a SMAD4-dependent effect. We next studied how BMP9-ALK1-SMAD4 signaling affected PTEN phosphorylation. We reasoned that the pathway could repress a kinase that phosphorylates PTEN at the Ser380/Thr382/383 sites. Two kinases are known to regulate these phosphorylation sites: LKB1 ( liver kinase B1) and CSNK2A2 (casein kinase 2), hereafter referred to as CK2. 34, 35 qPCR analysis showed that expression of the CK2A2 isoform was downregulated by BMP9 treatment in CTRL siRNA-transfected HUVECs. SMAD4 knockdown increased CK2 expression levels by 2-fold and inhibited BMP9-induced CK2 repression. In contrast, LKB1 levels were unaffected by BMP9 or SMAD4 siRNA treatment ( Figure 6C ). These data revealed CK2 as a candidate kinase that could act downstream of BMP9-SMAD4 to regulate PTEN phosphorylation.
To identify effects of CK2 on PTEN and AKT phosphorylation, we treated CTRL siRNA and SMAD4 siRNA transfected cells for 2 hours with TBCA, a selective and cell-permeable CK2 inhibitor (IC50 110nM). While BMP9 treatment failed to inhibit PTEN and AKT phosphorylation in the SMAD4 mutant cells, the CK2 inhibitor blocked PTEN and AKT phosphorylation in both CTRL and SMAD4-depleted cells ( Figure 6D and 6E) .
Next, we inhibited CK2 kinase activity in Smad4 iΔEC ;mTmG mice. Smad4 iΔEC intercrossed with mTmG mice allowed us to label GFP+ Smad4-deficient endothelial cells. Tx was injected at P0 to P2, the CK2 inhibitor was administered at P3 to P5, and the retinas were analyzed at P6 ( Figure 6F ). GFP+ vasculature in DMSO treated Smad4 iΔEC ; mTmG retinas was seen to form AVMs, while pups treated with the Ck2 inhibitor did not develop AVMs ( Figure 6G 
DISCUSSION
This study investigates the role of Smad4 in AVM formation and PI3K/AKT signaling. We show that loss of endothelial Smad4 induced retinal, cerebral and intestinal AVMs, similar to vascular malformations observed in human JP-HHT patients carrying SMAD4 loss of function mutations. Comparison with AVMs developing after inhibition of BMP9/10, Alk1, or Eng reveals highly similar characteristics in Smad4 iΔEC mice, including development of AVMs in areas subject to high shear stress, enhanced PI3K/AKT signaling, excessive angiogenesis and arterialvenous identity defects. The data strongly support that SMAD4 functions as a critical effector of AVM formation in mouse models of HHT (Figure 7) .
Because SMAD4 is a common downstream effector of all TGFβ signaling, the strong similarity to other HHT pathway knockouts and the predominance of AVM formation in postnatal retina, brain, and GI tract was actually surprising. Previous studies had demonstrated active TGFβ signaling, as well as functional proangiogenic BMP signaling, through ALK2 and ALK3 in ECs of the postnatal retina. Inducible, endothelial-specific knockout of each of these genes during the formation of the retinal superficial layer leads to very distinct phenotypic consequences on vascular development. [36] [37] [38] [39] It is currently unknown how these different pathways can mediate distinct effects on vascular development via a common downstream SMAD4 effector. However, weand others-did not observe AVM formation during the development of the superficial primary vascular plexus in the retina of Tgfβ pathway mutants or Alk2/3 mutant mice [36] [37] [38] [39] leading us to propose that BMP-ALK1 are the major upstream regulators of SMAD4 during this specific developmental step.
Despite the strong similarity between Alk1 and Smad4 mutant phenotypes, AVM formation is not strictly identical in these mice. AVMs develop with a lag period in Smad4 mutants when compared to Alk1 mutants, even though we find similar gene deletion efficiency and similar protein half-lives. We acknowledge that it is technically impossible for us to exclude that the presence and function of residual Smad4 protein in the mutants might contribute to the delay in AVM formation. However, the delayed AVM formation may also relate to Smad4-independent processes, for example via DROSHA-dependent microRNA processing. 16 Next, we find, in vitro, that flow enhances AKT activation and that this process is suppressed by BMP9 in an ALK1, but only partially SMAD4-dependent manner. Thus, a 2-pronged mechanism may lead to AVM formation: in a first step, loss of BMP9-ALK1 signaling prevents suppression of flow-induced AKT signaling through a SMAD4-independent mechanism, with loss of SMAD4 transcriptional activity further enhancing activation of the AKT pathway. Recent studies showed that AVM formation is dependent on blood flow. It is most striking that blocking blood flow in zebrafish Alk1 mutants prevented AVM formation, directly demonstrating that blood flow induces AVM formation in the absence of ALK1. 40 Next, several studies showed that wildtype endothelial cells within fully perfused vessels are polarized and migrate against the direction of blood flow, 17, [41] [42] [43] while their polarization and migration occurs in the opposite direction toward the flow in Alk1, Eng, and Smad4 mutant cells. 12, 17, 20, 44 Together with cell shape changes, altered identity and proliferation status, these migratory defects contribute to vessel enlargement and AVM formation. Last, BMP9/10-ALK1 signaling blockade in mice induces AVM formation in regions of high flow, and flow potentiates BMP9/10 signaling through ALK1 in an ENG-dependent manner. 23 Like BMP9/10-ALK1 blockade, 19, 23 we and others 13 show that SMAD4 signaling inhibition results in the formation of AVMs specifically in regions of high blood flow, whereas less perfused vasculature toward the angiogenic front develops hypervascularization. Physiological blood flow maintains endothelial quiescence by inhibiting proliferation and by inducing recruitment of pericytes, 27, 28 and Smad4-deficient retinas showed increased proliferation and decreased pericyte recruitment in regions with high flow, suggesting the convergence of the 2 mechanisms for development of HHT vascular lesions. Thus, flow is a major contributor to AVM formation, and potentiates BMP9-ALK1-ENG-SMAD4 signaling, but how flow and BMP9 cooperate together to instruct endothelial cell behavior and how lack of pathway function induced AVMs remained unclear.
A major finding reported here is that BMP9-ALK1-ENG-SMAD4 signaling mechanistically links flowsensing and AKT pathway activation. AKT is induced by growth factors such as VEGF (vascular endothelial growth factor), 17, 19 and also potently activated by shear stress, probably downstream of the VEGFR2-VE-Cadherin-PECAM1 (platelet and endothelial cell adhesion molecule 1) mechanosensory complex.
45 BMP9 signaling counteracts both flow and growth factor-induced AKT activation, revealing a negative feedback loop in which flow activates both AKT and ALK1-ENG-SMAD4 signaling, with the latter inhibiting the former (Figure 7) . The importance of this pathway for proper vascular morphogenesis in vivo is demonstrated by the presence of overactivated PI3K/AKT signaling in AVMs developing in high flow regions of the Alk1 or Smad4-deficient vasculature, and rescue of AVM formation by pharmacological inhibition of PI3K or genetic deletion of the major endothelial AKT1 isoform. In support of our findings, heterozygous inactivation of p110α was shown to rescue the vascular hyperplasia induced by heterozygous loss of Alk1 in mice, and increased expression of PI3K signaling components was also found in HHT2 patients. 22 Interesting questions for future studies concern the function of PI3K/AKT signaling in flow-migration coupling and the roles of downstream effectors such as pS6, FOXO1, and cMYC in AVM formation. Postnatal endothelial-specific deletion of Foxo1 and cMyc induce profound alterations of vascular development consistent with a possible effector 
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role. 32 However, besides PI3K/AKT, additional pathways are likely to operate during AVM formation. Loss of function mutations in human PTEN cause Cowden syndrome, which is associated with tissue overgrowth and occasional AVMs. Gain of function mutations in PI3K is associated with venous malformations, while AKTactivating mutations cause Proteus syndrome, which also leads to overgrowth of various tissues including the vasculature and occasional AVMs; [46] [47] [48] however, these lesions are distinct from vascular lesions in HHT.
In our experiments, we have found that Akt1 deletion did not prolong survival of the Smad4 mutant mice. While this could be due to defects in other SMAD4 upstream pathways, most likely the TGFß pathway that leads to intracranial hemorrhage, we cannot at this time exclude incomplete rescue of vascular lesion formation via PI3K/AKT inhibition.
Mechanistically, we have shown that BMP9-ALK1 signaling regulates PI3K/AKT signaling via SMAD4-dependent inhibition of CK2 expression. In silico analysis of the human and mouse CK2 promoter revealed several canonical SMAD binding elements. ChIP assays with a SMAD4 antibody in HUVECs followed by qPCR with primers against the regions containing the conserved SMAD binding elements showed that BMP9 treatment increased SMAD4 binding to the CK2 promoter (RO, LPF, RC, and KM, unpublished observations), suggesting that CK2 could be a direct SMAD4 target, but further experiments are needed to confirm a direct interaction (Figure 7) . CK2 phosphorylates the PTEN C terminus and inactivates PTEN by removing it from the membrane, 35 hence rendering it unable to inhibit PI3K. While the mechanistic basis how SMAD4 suppresses CK2 expression is currently under investigation, we found a specific increase in CK2 expression on SMAD4 deletion and CK2 downregulation by BMP9 in HUVECs. When HUVECs were treated with CK2 inhibitor, we observed a rescue in PTEN phosphorylation and inhibition of downstream AKT activation. Of note, the known CK2 substrates also include AKT Ser129, which may increase its catalytic activity, 49 thus CK2 inhibition may also affect AKT directly. Pharmacological inhibition of CK2 activity rescued AVM formation in Smad4-deficient retinas and also reduced the expression of AKT downstream signaling components, suggesting that CK2 might be a potential target to improve vascular anomalies in HHT patients. In summary, we show that BMP9-ALK1-ENG opposes growth factor and flow-induced AKT pathway activation in a SMAD4-dependent manner via repression of CK2. Disruption of this pathway induces AVM formation in regions of high flow.
Our data also provide a rationale for further studies of CK2 implication in JP-HHT patients. Although CK2 expression has not been studied directly in JP-HHT, multiple cancer types exhibit elevated CK2 expression and CK2 is involved in many key aspects of cancer including inhibition of apoptosis, modulation of signaling pathways, DNA damage response, and cell cycle regulation. 50 A number of available CK2 inhibitors have been shown to have activity against various cancers in vitro and in preclinical models. Some of these inhibitors are now undergoing exploration in clinical trials as well. We speculate that loss of SMAD4-mediated CK2 repression may contribute to elevated CK2 levels in the GI tract of JP-HHT patients, hence contributing to malignant transformation of intestinal polyps.
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